- US-listed companies
- MoonLake Immunotherapeutics
- Income statement
MoonLake ImmunotherapeuticsMLTX
Market cap
$984.88M
P/E ratio
| 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Research & development | - | - | 42 | 32 | 113 |
| Operating income | -105,755 | -4,570,345 | -65,061,417 | -54,123,096 | -143,091,082 |
| Operating expenses | - | - | 65 | 54 | 143 |
| Income before tax | - | - | -64,469,685 | -43,984,729 | -120,962,201 |
| Provision for income taxes | - | - | 36,366 | 94,388 | 282,199 |
| Effective tax rate (%) | - | - | |||
| Net income | -90,838 | -4,542,654 | -49,973,249 | -36,007,260 | -118,935,517 |
| Earnings per share | - | - | -1.7 | -0.73 | -1.89 |
| Diluted EPS | - | - | -1.7 | -0.73 | -1.89 |
| EBITDA | - | - | - | - |